The European Commission approved the deal, clearing the way for Danaher to complete the $6.8 billion purchase by the end of the month.
President and CEO J. Robert Hurley is now also interim Diagnostic Division President, while Scott Atkins was named president of the Life Science Division.
The company said that it anticipates regulatory approval from the European Commission on or about June 16 and to close the acquisition by the end of the month.
The company's Clinical Diagnostics segment was up 3 percent year over year, while Life Science slid 11 percent.
The trials will evaluate biomarker panels for lung, colon, and prostate cancer, and may include a comparison of proteomics-based lung cancer tests from Somalogic and Celera.
The deadline for the deal has been pushed back to April 27 from March 23.
In a research note, Jon Groberg wrote that in the near term firms with a larger consumables presence in Japan face greater revenue risk, while instrument firms face greater mid-term risk.
The firms have said they expect to complete the transaction in the first half of this year.
Robert Friel today denied a report that the company is seeking a buyer after failing to land Beckman Coulter.
Shares of PerkinElmer climbed more than 9 percent on Thursday after a report was published saying that the firm is exploring being bought out amid a failed bid to acquire Beckman Coulter.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.